Publications by authors named "H Gisslinger"
Article Synopsis
- - A new framework for defining anemia severity and treatment response in myelofibrosis (MF) aims to improve clinical studies and comparisons as new drugs emerge in this area.
- - The revised criteria will address gender differences in hemoglobin levels and update the definition of transfusion-dependent anemia (TDA) to align with current practices.
- - The updated guidelines introduce specific eligibility thresholds for hemoglobin levels and establish distinct response criteria (major vs. minor) while maintaining a 12-week observation period on treatment.
Article Synopsis
- Cast nephropathy (CN) is a major cause of acute kidney injury in multiple myeloma (MM), and the study aims to identify why some patients recover kidney function while others don't.
- A retrospective analysis of 28 patients with CN showed that younger patients with a hematologic response to treatment had better kidney recovery and overall survival.
- Early initiation of anti-myeloma therapy and a significant relationship between kidney biopsy scores and dialysis requirements were also highlighted, indicating that timely treatment and deeper hematologic responses can positively impact kidney recovery and patient outcomes.
Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials.
Turk J Haematol
December 2023
Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free survival. Data support the use of RopegIFN in both early PV therapy and second-line and beyond.
View Article and Find Full Text PDFArticle Synopsis
- Hydroxyurea (HU) is a widely used first-line treatment for polycythemia vera (PV), but 15%-24% of patients experience resistance or intolerance to it.
- A phase IV observational study in Europe evaluated ruxolitinib's effectiveness and safety in PV patients resistant or intolerant to HU, following 350 patients for 24 months.
- Results showed that 68.2% of patients achieved hematocrit control, 85.1% had no need for phlebotomy during the study, and ruxolitinib was well tolerated despite some treatment-related adverse events.